Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Athersys Rose 26.5% in May

By Maxx Chatsko – Jun 9, 2020 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.

What happened

Shares of Athersys (ATHX 18.38%) rose over 26% last month, according to data provided by S&P Global Market Intelligence. The stem cell stock's movement in May can primarily be described as a recovery from a lousy April, but two business updates certainly helped.

In the first week of May, Athersys announced the U.S. Food and Drug Administration (FDA) had authorized the initiation of a phase 2/3 trial in COVID-19-induced acute respiratory distress syndrome (ARDS). The development was followed by additional business updates packed into the discussion of first-quarter 2020 operating results. That was enough to fuel the ascension of this small-cap stock -- for now. 

A hand placing blocks with rising arrows on them in ascending rows of blocks.

Image source: Getty Images.

So what

Athersys is throwing its lead drug candidate, MultiStem, at the coronavirus pandemic. More specifically, the stem cell treatment will be administered to individuals with COVID-19-induced ARDS, who often require mechanical ventilation. It helps that the company had been studying the drug candidate's potential to treat ARDS before the health crisis struck.

However, investors might be getting a little carried away. The results from the phase 1 study evaluating MultiStem in ARDS weren't very impressive and weren't very detailed. 

Athersys and other stem cell companies appear to be riding a wave of enthusiasm for Mesoblast, which reported encouraging results for its stem cell treatment in a small, 12-patient study in COVID-19-induced ARDS. But it's important to point out that Athersys and Mesoblast utilize different types of stem cells. 

Now what

Even with increased attention, Athersys is valued at a lowly $570 million. That suggests Wall Street still isn't very enthusiastic about the stem cell stock, which isn't too surprising considering the company hasn't successfully commercialized MultiStem for a single disease despite over a decade of clinical trials. Investors need to remain grounded until indisputable clinical results are published.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Athersys, Inc. Stock Quote
Athersys, Inc.
$2.19 (18.38%) $0.34
Mesoblast Limited Stock Quote
Mesoblast Limited
$2.73 (7.27%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.